Neurocrine Biosciences (NBIX) Operating Expenses (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Operating Expenses of $807.5 million for Q2 2026, up 49.01% year-over-year from $541.9 million in Q2 2025, and up 30.01% on a QoQ basis from $621.1 million in Q1 2026.
Neurocrine Biosciences (NBIX) Operating Expenses (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Operating Expenses for 17 years, with the latest figure at $807.5 million in Q2 2026.
- Operating Expenses for Q2 2026 came in at $807.5 million, up 49.01% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.6 billion (up 28.0% YoY), and the FY2025 annual result was $2.2 billion, up 25.58% from the prior year.
- Operating Expenses grew to $807.5 million in Q2 2026, from $621.1 million in the prior quarter.
- Over five years, Operating Expenses peaked at $807.5 million in Q2 2026 and troughed at $300.1 million in Q3 2022.
- A 5-year average of $462.8 million and a median of $441.6 million in 2024 frame the typical range for Operating Expenses.
- The widest annual swing landed in 2023, when Operating Expenses soared 73.85%; it then slipped 22.18% in 2024.
- A 5-year view of Operating Expenses shows it stood at $308.6 million in 2022, then increased by 18.24% to $364.9 million in 2023, then jumped by 33.1% to $485.7 million in 2024, then climbed by 22.42% to $594.6 million in 2025, then soared by 35.81% to $807.5 million in 2026.
- Per Business Quant data, the three most recent Operating Expenses figures were $807.5 million in Q2 2026, $621.1 million in Q1 2026, and $594.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 1.29 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 215.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | -2.85 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 452.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 1.45 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 807.50 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 550.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 477.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 807.50 Mn |
| Mar 31, 2026 | 621.10 Mn |
| Dec 31, 2025 | 594.60 Mn |
| Sep 30, 2025 | 555.90 Mn |
| Jun 30, 2025 | 541.90 Mn |
| Mar 31, 2025 | 549.00 Mn |
| Dec 31, 2024 | 485.70 Mn |
| Sep 30, 2024 | 438.30 Mn |
| Jun 30, 2024 | 444.80 Mn |
| Mar 31, 2024 | 416.00 Mn |
| Dec 31, 2023 | 364.90 Mn |
| Sep 30, 2023 | 357.60 Mn |
| Jun 30, 2023 | 379.10 Mn |
| Mar 31, 2023 | 534.60 Mn |
| Dec 31, 2022 | 308.60 Mn |
| Sep 30, 2022 | 300.10 Mn |
| Jun 30, 2022 | 323.50 Mn |
| Mar 31, 2022 | 307.50 Mn |
| Dec 31, 2021 | 348.30 Mn |
| Sep 30, 2021 | 251.50 Mn |